We are a fast-growing, pre-clinical-stage biopharmaceutical company developing tumor-specific T cell receptor (TCR) therapies ... . Our dynamic, international team sets out with the ambitious goal to revolutionize the TCR landscape using our unique and proprietary transgenic HuTCR mouse platform to produce fully human TCRs for the treatment of cancer. To achieve this ambitious goal, we have successfully completed Series A financing with top-tier investors in August 2020. read more